About: Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.43 (-1.79%)
OCUL NASDAQ Ocular Therapeutix Inc
Ocular Therapeutix Inc share price
OCUL price activity
Last Price
$7.430
Change (24hr)
-0.14 USD (-1.79%)
Volume
1.41M
Volume (4w avg)
-
Open
$7.55
Day Range
$7.43 - $7.55
Previous Close
$7.56
Last Trade
13 Oct, 5:33 pm GMT+0
Delayed
13 Oct, 5:33 pm GMT+0
OCUL price performance
Delayed
13 Oct, 5:33 pm GMT+0
OCUL Market Signals